Citations

Clear

78 citation(s) found for "Smith, Michael".

Characteristics of Patients With the Arrhythmogenic Mitral Valve Prolapse Syndrome and Sudden Cardiac Arrest and Sustained Ventricular Arrhythmias
Chakrabarti, Apurba , Giudicessi, John R. , Delling, Francesca N. , Dixit, Shalini , Lee, Yoo Jin , Muser, Daniele , Magnani, Silvia , Wijngaarden, Aniek L. van , Miller, Marc A. , Gandhi, Jonathan, Font, Jonaz , Martins, Raphaël P. , McCaffrey, James A. , Chapagain, Himal , Mathew, Don , Kancharla, Krishna , Syed, Faisal F. , Abid, Ahad, Cerbin, Lukasz , Garg, Lohit , Natale, Andrea , Enríquez, Andrés , Bogun, Frank , Ackerman, Michael J. , Liang, Jackson J. , Ezzeddine, Fatima , Delling, Francesca N , Lee, Yoo Jin , Muser, Daniele , Magnani, Silvia , van Wijngaarden, Aniek , Marsan, Nina Ajmone , Trivieri, Maria G , Font, Jonaz , Martins, Raphael , McCaffrey, James A , Santangeli, Pasquale , Marchlinski, Francis E , Chapagain, Himal , Mathew, Don , Kancharla, Krishna , Syed, Faisal F , Abid, Ahad , Tzou, Wendy , Della Rocca, Domenico G , Natale, Andrea , Mohanty, Sanghamitra , Sheldon, Seth H. , Kuo, Ling , Haugaa, Kristina , Aabel, Eivind W , Enriquez, Andres , Maeda, Shingo , Deshmukh, Amrish , Ackerman, Michael J , Liang, Jackson , Ezzeddine, Fatima M. , Marsan, Nina Ajmone , Santangeli, Pasquale , Marchlinski, Francis E. , Tzou, Wendy S. , Rocca, Domenico G. Della , Haugaa, Kristina H. , Aabel, Eivind W. , Deshmukh, Amrish , Ghannam, Michael

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | February 20, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circep.124.013099 | PMID 39973752 Get It

BACKGROUND: Patients with arrhythmogenic mitral valve prolapse syndrome are at increased risk for life-threatening ventricular arrhythmias, but studies have been limited by small sample sizes. We sought to assemble an international arrhythmogenic mitral valve prolapse syndrome registry to delineate the clinical, imaging, and treatment characteristics of patients with arrhythmogenic mitral valve prolapse syndrome who survived sudden cardiac arrest (SCA) or had sustained ventricular tachycardia (VT) or ventricular fibrillation. METHODS: In this descriptive registry, we characterized patients with arrhythmogenic mitral valve prolapse syndrome who survived SCA, sustained VT, or ventricular fibrillation. Deidentified data were abstracted locally and combined centrally. RESULTS: We included 148 patients who had SCA or VT/ventricular fibrillation. Patients had a mean age of 43.7±15.4 years; 68% were women, 73% had bileaflet prolapse, 65% had mitral annular disjunction, 67% had nonsustained VT, and 59% had inferolateral T-wave inversions. Syncope (n=54, 48%) and anterolateral T-wave inversion (n=26, 22%) were relatively common. Catheter ablation was performed in 50 (35%) patients for premature ventricular complexes and in 18 (17.7%) patients for VT. Sites of origin for arrhythmias were commonly in the papillary muscles, fascicles, mitral annulus, and inferior/inferolateral left ventricle. CONCLUSIONS: In this international descriptive registry of patients with arrhythmogenic mitral valve prolapse syndrome and SCA, patients were young, women, and had bileaflet mitral valve prolapse, mitral annular disjunction, inferolateral T-wave inversions, and nonsustained VT. A history of syncope and anterolateral T-wave inversions was relatively common in patients who survived SCA or sustained VT/ventricular fibrillation.
S647 Balloon Cryotherapy is Highly Effective in Patients With Poor Response to Radiofrequency Ablation Therapy for Dysplastic Barrett’s Esophagus: Preliminary Results from the NO FEAR-BE Study
Shaheen, Nicholas J. , Iyer, Prasad G. , Khara, Harshit S. , Elias, Puja S., Chak, Amitabh , Shafa, Shervin , Peter, Shajan, Smith, Michael S. , Moist, Susan E., Walker, Kacie B, Kim, Julia , Jones, Carson, Canto, Marcia Irene , Cotton, Cary C. , Abrams, Julian A , Thosani, Nirav C , Cortright, Lindsay M. , Walker, Kacie B., Jones, Carson, Trindade, Arvind J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S448-S448

10.14309/01.ajg.0001031956.24377.ea Get It

Frequency and Genotype‐Dependence of intrinsic chronotropic insufficiency among patients with congenital long QT syndrome
Kulkarni, Veda, Pinsky, Alexa M. , Bos, J. Martijn , Bains, Sahej , Giudicessi, John R. , Allison, Thomas G. , Ackerman, Michael J. , Kulkarni, Veda K, Bains, Sahej , Giudicessi, J R , Ackerman, Michael J , Bos, Johan M , Neves, Raquel

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 21, 2024 | Volume: 36 | Issue: 1 | Pages: 17-23

10.1111/jce.16471 | PMID 39428612 Get It

AbstractIntroductionLong QT syndrome (LQTS) is a cardiac channelopathy characterized by QT prolongation and a potential for arrhythmic syncope, sudden cardiac arrest or deaths (SCA/SCD). It has been speculated that patients with LQTS might have a primary sinoatrial node (SAN) phenotype of chronotropic insufficiency (CI). This has not been demonstrated convincingly before because of the potentially confounding effects of beta blocker (BB) therapy. Herein, we set out to determine whether untreated patients with LQTS demonstrate intrinsic CI.Methods and ResultsA retrospective review of all treadmill exercise stress tests (TEST) was performed on patients with one of the three most common LQTS genotypes: LQT1, LQT2, and LQT3. For each patient, the first TEST completed while off BB was analyzed. Patients with prior left cardiac sympathetic denervation (LCSD) therapy were excluded. CI was defined as having an age‐ and gender‐predicted peak heart rate (HR) < 85% and/or a predicted HR reserve (HRR) < 80%. Overall, 463 LQTS patients (245 LQT1, 125 LQT2, and 93 LQT3) were included (267 female [58%]; mean age at time of TEST [29 ± 17 years]). Mean % predicted peak HR for all LQTS patients was 87.6% (range 42.9% ‐ 119.1%) and mean % predicted HRR was 80% (range 19.1% ‐ 153%). Overall, half of all LQTS patients (n = 234; 51%) displayed CI; 64% of patients with LQT1 (n = 157), 37% with LQT2 (n = 46), and 33% with LQT3 (n = 31). Patients with LQT1 were most likely to exhibit CI compared to patients with LQT2 (p < .0001) and LQT3 (p < .0001). CI was significantly more common in LQT1 compared to controls (p < .0001), while there was no difference between LQT2 (p = .5) or LQT3 and controls (p > .9). Presence of CI was not a predictor of LQTS‐associated symptoms, BB side effects or likelihood of future breakthrough cardiac events (BCE).ConclusionsPatients with LQTS, particularly LQT1, demonstrate a SAN phenotype of CI. If assessing BB therapy effect by impact on peak HR, the patient's pretreatment peak HR, rather than an age‐ and gender‐predicted maximum HR, should be used.
Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings: Clinical Practice Guideline
Hadland, Scott E. , Agarwal, Rita , Raman, Sudha R. , Bryl, Amy W., Michel, Jeremy J. , Renny, Madeline H. , Larson-Steckler, Beth, Wexelblatt, Scott L. , Wilder, Robert T., Flinn, Susan K., Humphrey, Lisa, Walker-Harding, Leslie, Webb, Michael, Emmer, Suzanne, Okechukwu, Kymika, Nunnery, Cordarrell, Smith, Michael John , Kelley‐Quon, Lorraine I. , Raval, Mehul V. , Humphrey, Lisa, Walker-Harding, Leslie, Webb, Michael, Emmer, Suzanne, Okechukwu, Kymika, Nunnery, Cordarrell

Mayo Clinic

Pediatrics | September 30, 2024 | Volume: 154 | Issue: 5 | Pages: No page available

10.1542/peds.2024-068752 | PMID 39344439 Get It

This is the first clinical practice guideline (CPG) from the American Academy of Pediatrics outlining evidence-based approaches to safely prescribing opioids for acute pain in outpatient settings. The central goal is to aid clinicians in understanding when opioids may be indicated to treat acute pain in children and adolescents and how to minimize risks (including opioid use disorder, poisoning, and overdose). The document also seeks to alleviate disparate pain treatment of Black, Hispanic, and American Indian/Alaska Native children and adolescents, who receive pain management that is less adequate and less timely than that provided to white individuals. There may also be disparities in pain treatment based on language, socioeconomic status, geographic location, and other factors, which are discussed. The document recommends that clinicians treat acute pain using a multimodal approach that includes the appropriate use of nonpharmacologic therapies, nonopioid medications, and, when needed, opioid medications. Opioids should not be prescribed as monotherapy for children or adolescents who have acute pain. When using opioids for acute pain management, clinicians should prescribe immediate-release opioid formulations, start with the lowest age- and weight-appropriate doses, and provide an initial supply of 5 or fewer days, unless the pain is related to trauma or surgery with expected duration of pain longer than 5 days. Clinicians should not prescribe codeine or tramadol for patients younger than 12 years; adolescents 12 to 18 years of age who have obesity, obstructive sleep apnea, or severe lung disease; to treat postsurgical pain after tonsillectomy or adenoidectomy in patients younger than 18 years; or for any breastfeeding patient. The CPG recommends providing opioids when appropriate for treating acutely worsened pain in children and adolescents who have a history of chronic pain; clinicians should partner with other opioid-prescribing clinicians involved in the patient’s care and/or a specialist in chronic pain or palliative care to determine an appropriate treatment plan. Caution should be used when treating acute pain in those who are taking sedating medications. The CPG describes potential harms of discontinuing or rapidly tapering opioids in individuals who have been on stable, long-term opioids to treat chronic pain. The guideline also recommends providing naloxone and information on naloxone, safe storage and disposal of opioids, and direct observation of medication administration. Clinicians are encouraged to help caregivers develop a plan for safe disposal. The CPG contains 12 key action statements based on evidence from randomized controlled trials, high-quality observational studies, and, when studies are lacking or could not feasibly or ethically be conducted, from expert opinion. Each key action statement includes a level of evidence, the benefit-harm relationship, and the strength of recommendation.
Multiplexed Assays of Variant Effect and Automated Patch Clamping Improve KCNH2 -LQTS Variant Classification and Cardiac Event Risk Stratification
O’Neill, Matthew J. , Ng, Chai‐Ann , Aizawa, Takanori , Sala, Luca , Bains, Sahej , Winbo, Annika , Ullah, Rizwan , Shen, Qianyi, Tan, Chek-Ying, Kozek, Krystian A. , Vanags, Loren , Mitchell, Devyn , Shen, Alex , Kashiwa, Asami , Musu, Giulia , Bos, J. Martijn , Giudicessi, John R. , Bledsoe, Xavier , Gamazon, Eric R. , Glazer, Andrew M. , Roden, Dan M. , Stiles, Rachael, Agee, Taylor , Johnson, Christopher N. , Ackerman, Michael J. , Ohno, Seiko , Vandenberg, Jamie I. , Kroncke, Brett M. , Kozek, Krystian , Mitchell, Devyn W , Wada, Yuko , Kashiwa, Asami , Crotti, Lia , Dagradi, Federica , Spazzolini, Carla , Neves, Raquel Almeida Lopes , Bos, Johan M , Giudicessi, J R , Bledsoe, Xavier , Lancaster, Megan C , Glazer, Andrew M , Knollmann, Bjorn C , Salem, Joe-Elie , Earle, Nikki , Agee, Taylor , Johnson, Christopher N , Horie, Minoru , Skinner, Jonathan R , Ackerman, Michael J , Schwartz, Peter J. , Ohno, Seiko , Vandenberg, Jamie I , Sala, Luca , Bains, Sahej , Wada, Yuko , Dagradi, Federica , Spazzolini, Carla , Neves, Raquel , Roden, Dan M. , Weile, Jochen , Roth, Frederick P. , Salem, Joe‐Elie , Skinner, Jonathan R.

Mayo Clinic

Circulation | September 24, 2024 | Volume: 150 | Issue: 23 | Pages: 1869-1881

10.1161/circulationaha.124.069828 | PMID 39315434 Get It

BACKGROUND: Long QT syndrome is a lethal arrhythmia syndrome, frequently caused by rare loss-of-function variants in the potassium channel encoded by KCNH2 . Variant classification is difficult, often because of lack of functional data. Moreover, variant-based risk stratification is also complicated by heterogenous clinical data and incomplete penetrance. Here we sought to test whether variant-specific information, primarily from high-throughput functional assays, could improve both classification and cardiac event risk stratification in a large, harmonized cohort of KCNH2 missense variant heterozygotes. METHODS: We quantified cell-surface trafficking of 18 796 variants in KCNH2 using a multiplexed assay of variant effect (MAVE). We recorded KCNH2 current density for 533 variants by automated patch clamping. We calibrated the strength of evidence of MAVE data according to ClinGen guidelines. We deeply phenotyped 1458 patients with KCNH2 missense variants, including QTc, cardiac event history, and mortality. We correlated variant functional data and Bayesian long QT syndrome penetrance estimates with cohort phenotypes and assessed hazard ratios for cardiac events. RESULTS: Variant MAVE trafficking scores and automated patch clamping peak tail currents were highly correlated (Spearman rank-order ρ=0.69; n=433). The MAVE data were found to provide up to pathogenic very strong evidence for severe loss-of-function variants. In the cohort, both functional assays and Bayesian long QT syndrome penetrance estimates were significantly predictive of cardiac events when independently modeled with patient sex and corrected QT interval (QTc); however, MAVE data became nonsignificant when peak tail current and penetrance estimates were also available. The area under the receiver operator characteristic curve for 20-year event outcomes based on patient-specific sex and QTc (area under the curve, 0.80 [0.76–0.83]) was improved with prospectively available penetrance scores conditioned on MAVE (area under the curve, 0.86 [0.83–0.89]) or attainable automated patch clamping peak tail current data (area under the curve, 0.84 [0.81–0.88]). CONCLUSIONS: High-throughput KCNH2 variant MAVE data meaningfully contribute to variant classification at scale, whereas long QT syndrome penetrance estimates and automated patch clamping peak tail current measurements meaningfully contribute to risk stratification of cardiac events in patients with heterozygous KCNH2 missense variants.
B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
Bennett, Jeffrey L. , Pittock, Sean J. , Paul, Friedemann , Kim, Ho Jin , Irani, Sarosh R. , O'Connor, Kevin C., Patterson, Kristina R. , Gunsior, Michele , Mittereder, Nanette , Rees, William A. , Cimbora, Daniel , Pittock, S J , Cree, Bruce Ac , Bennett, Jeffrey L , Irani, Sarosh R , Paul, Friedemann , Smith, Michael A. , Cree, Bruce

Mayo Clinic

Annals of Clinical and Translational Neurology | September 2, 2024 | Volume: 11 | Issue: 10 | Pages: 2792-2798

10.1002/acn3.52171 | PMID 39222408 Get It

Abstract This post hoc analysis of the randomized, placebo‐controlled N‐MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B‐cell subsets and aquaporin‐4 immunoglobulin G (AQP4‐lgG) titers and attacks. Among participants receiving placebo, CD20 + and CD27 + B‐cell counts were modestly increased from the pre‐attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre‐attack visit ( p = 0.016) and from baseline to attack ( p = 0.009). With inebilizumab treatment, B‐cell subset counts decreased and did not increase with attacks. No difference in change of AQP4‐IgG titers from baseline to time of attack was observed.
KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome
Bains, Sahej , Giammarino, Lucilla , Nimani, Saranda , Alerni, Nicolò , Tester, David J. , Kim, C.S. John, Christoforou, Nicolas , Louradour, Julien , Beslac, Olgica, Barbieri, Miriam , Matas, Lluis , Hof, Thomas , López, Rubén , Perez‐Feliz, Stefanie , Casalta, L.G. Garcia, Jurgensen, Jacqulyn, Bego, Mariana G. , Keyes, Lisa R., Owens, Jane , Pinkstaff, Jason, Koren, Gideon , Zehender, Manfred, Brunner, Michael, Casoni, Daniela , Brooks, Gabriel , Ackerman, Michael J. , Odening, Katja E. , Brunner, Michael , Praz, Fabien , Haeberlin, Andreas , Ackerman, Michael J , Odening, Katja E , Bains, Sahej , Horváth, András , Parodi, Chiara, Barry, Michael A. , Praz, Fabien

Mayo Clinic

European Heart Journal | August 8, 2024 | Volume: 45 | Issue: 36 | Pages: 3751-3763

10.1093/eurheartj/ehae476 | PMID 39115049 Get It

Abstract Background and Aims Type 1 long QT syndrome (LQT1) is caused by pathogenic variants in the KCNQ1-encoded Kv7.1 potassium channels, which pathologically prolong ventricular action potential duration (APD). Herein, the pathologic phenotype in transgenic LQT1 rabbits is rescued using a novel KCNQ1 suppression-replacement (SupRep) gene therapy. Methods KCNQ1-SupRep gene therapy was developed by combining into a single construct a KCNQ1 shRNA (suppression) and an shRNA-immune KCNQ1 cDNA (replacement), packaged into adeno-associated virus serotype 9, and delivered in vivo via an intra-aortic root injection (1E10 vg/kg). To ascertain the efficacy of SupRep, 12-lead electrocardiograms were assessed in adult LQT1 and wild-type (WT) rabbits and patch-clamp experiments were performed on isolated ventricular cardiomyocytes. Results KCNQ1-SupRep treatment of LQT1 rabbits resulted in significant shortening of the pathologically prolonged QT index (QTi) towards WT levels. Ventricular cardiomyocytes isolated from treated LQT1 rabbits demonstrated pronounced shortening of APD compared to LQT1 controls, leading to levels similar to WT (LQT1-UT vs. LQT1-SupRep, P &lt; .0001, LQT1-SupRep vs. WT, P = ns). Under β-adrenergic stimulation with isoproterenol, SupRep-treated rabbits demonstrated a WT-like physiological QTi and APD90 behaviour. Conclusions This study provides the first animal-model, proof-of-concept gene therapy for correction of LQT1. In LQT1 rabbits, treatment with KCNQ1-SupRep gene therapy normalized the clinical QTi and cellular APD90 to near WT levels both at baseline and after isoproterenol. If similar QT/APD correction can be achieved with intravenous administration of KCNQ1-SupRep gene therapy in LQT1 rabbits, these encouraging data should compel continued development of this gene therapy for patients with LQT1.
Remimazolam As a Sole Sedative Agent for Gastrostomy Tubes Placed in the Interventional Radiology Suite: A Case Series
Shapiro, Anna Bovill , Smith, Michael A. , Moshe, Christine , Moshe, Christine T, Frey, Gregory T, Frey, G. , Chadha, Ryan

Mayo Clinic

A&A Practice | August 6, 2024 | Volume: 18 | Issue: 8 | Pages: e01839

10.1213/xaa.0000000000001839 | PMID 39105528 Get It

Remimazolam is an ultrashort acting intravenous sedative-hypnotic approved for procedural sedation. We report a series of 8 cases of radiographically placed gastrostomy tubes using remimazolam as the sole anesthetic agent. Interventional radiology (IR) gastrostomy tube placement entails anesthetizing often complex patients in a nonoperating room environment. All 8 patients reported here underwent successful gastrostomy tube placement without the need for conversion to general anesthesia. Remimazolam is a feasible option to sedate patients for gastrostomy tube placement in the IR suite.
Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study
Lampert, Rachel , Day, Sharlene M. , Ainsworth, Barbara E. , Burg, Matthew M. , Marino, Bradley S. , Salberg, Lisa , Tome, Maite , Abrams, Dominic J. , Aziz, Peter F. , Barth, Cheryl , Behr, Elijah R. , Bell, Cheyanne , Berul, Charles I. , Bos, J. Martijn , Cannom, David S. , Cannon, Bryan C. , Concannon, Maryann, Czosek, Richard J. , Dubin, Anne M. , Dziura, James , Erickson, Christopher C. , Etheridge, Susan P. , Gray, Belinda , Haglund-Turnquist, Carla , Johnsrude, Christopher L. , Lara, Alice, Saarel, Elizabeth V. , Sanatani, Shubhayan , Shah, Maully J. , Simone, Laura, Tomaselli, Gordon F., Ware, James S. , Zaręba, Wojciech , Ackerman, Michael J. , Day, Sharlene , Burg, Matthew , Tome Esteban, Maria Teresa , Bos, Johan M , Cannon, Bryan C , Cerrone, Marina , Czosek, Richard J , Dubin, Anne M , Dziura, James , Erickson, Christopher C , Estes, N.A. Mark , Etheridge, Susan P , Goldenberg, Ilan , Gray, Belinda , Haglund-Turnquist, Carla M , Harmon, Kimberly G , James, Cynthia A , Johnsrude, Christopher , Kannankeril, Prince J , Law, Ian H , Link, Mark S. , Molossi, Silvana M , Olshansky, Brian , Noseworthy, Peter A , Saarel, Elizabeth V , Sanatani, Shubhayan , Shah, Maully , Skinner, Jonathan R , Ware, James S , Webster, Gregory , Zareba, Wojciech , Zipes, Douglas P , Ackerman, Michael J , Behr, Elijah Raphael , Abrams, Dominic J , Bradley, David J. , Cerrone, Marina , Goldenberg, Ilan , Harmon, Kimberly G. , James, Cynthia A. , Kannankeril, Prince J. , Law, Ian H. , Li, Fangyong , Olshansky, Brian , Noseworthy, Peter A. , Skinner, Jonathan R. , Webster, Gregory , Zipes, Douglas P.

Mayo Clinic

Circulation | July 25, 2024 | Volume: 150 | Issue: 7 | Pages: 516-530

10.1161/circulationaha.123.067590 | PMID 39051104 Get It

BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.